Iovance Biotherapeutics Ownership | Who Owns Iovance Biotherapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Iovance Biotherapeutics Ownership Summary


Iovance Biotherapeutics is owned by 63.59% institutional investors, 0.30% insiders, and 36.10% retail investors. Mhr fund management is the largest institutional shareholder, holding 8.66% of IOVA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.83% of its assets in Iovance Biotherapeutics shares.

IOVA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockIovance Biotherapeutics63.59%0.30%36.10%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Mhr fund management28.97M8.66%$62.86M
Blackrock21.23M7.97%$170.23M
Blackrock funding, inc. /de25.96M7.76%$56.33M
Vanguard group24.06M7.19%$52.21M
State street13.31M3.98%$28.88M
Invenomic capital management lp10.54M3.15%$22.88M
Long focus capital management9.12M2.73%$19.78M
Palo alto investors lp7.62M2.28%$16.53M
Geode capital management6.87M2.05%$14.91M
Goldman sachs group6.58M1.97%$14.27M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mhr fund management28.97M6.16%$62.86M
Palo alto investors lp7.62M3.06%$16.53M
B group1.50M2.39%$3.25M
Orion investment1.85M1.28%$4.02M
Cm management700.00K1.27%$1.52B
Invenomic capital management lp10.54M1.11%$22.88M
Parametrica management195.88K0.66%$425.06K
Long focus capital management9.12M0.65%$19.78M
Kennondale capital management318.19K0.53%$690.47K
Boxer capital750.00K0.32%$6.01M

Top Buyers

HolderShares% AssetsChange
Palo alto investors lp7.62M3.06%4.19M
State street13.31M0.00%3.42M
Blackrock funding, inc. /de25.96M0.00%2.72M
Invenomic capital management lp10.54M1.11%2.25M
Goldman sachs group6.58M0.00%1.83M

Top Sellers

HolderShares% AssetsChange
Perceptive advisors---12.71M
Hood river capital management---9.22M
Renaissance---4.89M
Macquarie group---4.79M
Artisan partners limited partnership---4.41M

New Positions

HolderShares% AssetsChangeValue
Artal group1.01M0.21%1.01M$8.11M
Susquehanna portfolio strategies912.10K0.03%912.10K$1.98M
Mirador capital partners lp515.02K0.16%515.02K$1.12M
Norges bank416.24K0.00%416.24K$3.08M
Cinctive capital management lp195.29K0.02%195.29K$423.78K

Sold Out

HolderChange
Global financial private client-4.00
Sjs investment consulting-4.00
Nbc securities-4.00
Capital performance advisors llp-11.00
Bell investment advisors-43.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20252470.82%212,726,6064.22%631.71%118-4.07%69-1.43%
Jun 30, 2025250-18.03%220,042,797-8.11%651.20%125-19.87%74-16.85%
Mar 31, 202524-92.48%69,746,593-71.12%210.34%12-92.36%4-95.40%
Dec 31, 2024193-35.02%100,034,590-57.33%320.55%92-39.07%50-37.50%
Sep 30, 2024292-5.19%234,393,8080.82%771.01%149-17.22%80-2.44%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv9.67M2.83%-792.50K
Vanguard US Total Market Shares ETF8.71M2.66%762.45K
iShares Russell 2000 ETF6.18M1.71%-
Hood River Small-Cap Growth Instl5.10M1.53%-
Macquarie Small Cap Core I4.08M1.22%56.67K
Vanguard Small Cap Index3.65M1.07%-24.46K
SPDR® S&P Biotech ETF3.56M0.98%7.96K
Invenomic Institutional3.28M0.98%3.28M
Delaware Small Cap Core I2.61M0.86%1.84M
Vanguard Institutional Extnd Mkt Idx Tr2.70M0.79%-1.24M

Recent Insider Transactions


DateNameRoleActivityValue
Jun 05, 2025Kirby Daniel Gordon Chief Commercial OfficerBuy$55.20K
May 23, 2025Puri Raj K. Chief Regulatory OfficerBuy$9.74K
May 14, 2025Vogt Frederick G Interim CEO & General CounselBuy$42.25K
Nov 12, 2024Maynard Ryan D-Sell$503.00K
Feb 20, 2024MCPEAK MERRILL A-Buy$2.29M

Insider Transactions Trends


DateBuySell
2025 Q4--
2025 Q3--
2025 Q23-
2025 Q1--
2024 Q4-1

IOVA Ownership FAQ


Who Owns Iovance Biotherapeutics?

Iovance Biotherapeutics shareholders are primarily institutional investors at 63.59%, followed by 0.30% insiders and 36.11% retail investors. The average institutional ownership in Iovance Biotherapeutics's industry, Biotech Stocks , is 45.24%, which Iovance Biotherapeutics exceeds.

Who owns the most shares of Iovance Biotherapeutics?

Iovance Biotherapeutics’s largest shareholders are Mhr fund management (28.97M shares, 8.66%), Blackrock (21.23M shares, 7.97%), and Blackrock funding, inc. /de (25.96M shares, 7.76%). Together, they hold 24.39% of Iovance Biotherapeutics’s total shares outstanding.

Does Blackrock own Iovance Biotherapeutics?

Yes, BlackRock owns 7.97% of Iovance Biotherapeutics, totaling 21.23M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 170.23M$. In the last quarter, BlackRock increased its holdings by 1.3M shares, a 6.50% change.

Who is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Mhr fund management is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 6.16% of its assets in 28.97M Iovance Biotherapeutics shares, valued at 62.86M$.

Who is the top mutual fund holder of Iovance Biotherapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Iovance Biotherapeutics shares, with 2.83% of its total shares outstanding invested in 9.67M Iovance Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools